The Imugene (ASX:IMU) share price has fallen 14% in the last 5 days

After hitting a record high in May, Imugene shares slid 14% this week. Let's take a look.

| More on:
A doctor looks unsure, indicating share price uncertainty for ASX medical companies

Image source: Getty images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Imugene Limited (ASX: IMU) continue to be among the most traded shares on the market. Unfortunately for investors, the Immugene share price has been on a heavy losing streak this week, falling 14% in the last 5 days.

Imugene is a clinical stage immuno-oncology company currently developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.

The company is conducting a number of trials including HER-Vaxx, an immunotherapy to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The Imugene share price has been volatile recently, rising from 12 cents in April to a record high of 50 cents at the end of May, more than tripling its value.

June has brought a change in fortune, however, with shares sliding back to their current price of 32.5 cents apiece. With no negative announcements from the company, let's take a look at what's been happening recently.

Recent announcements

Since April, the company has released several announcements that have sent the Imugene share price surging higher.

One significant release came on 21 April when Imugene announced that the second clinical endpoint for its HER-Vaxx clinical studies had been met.

On 18 May, Imugene declared it had entered into an agreement with City of Hope, an independent cancer research and treatment centre, to license the patent for its CD19 therapy.

It was a world first, with the technology under the license being an extension of chimeric antigen receptor (CAR) T cell cancer therapy, which has the potential to treat solid cancers. Imugene plans to begin its first clinical trial of CD19 in 2022.

Following that announcement, banking firm FROTH Capital raised the Immugene share price target to 42 cents. This was based on a number of factors, including the projected future revenue of Imugene CHECKvacc, HER-Vaxx, and PD1-Vaxx trials.

With the biotech's surging share price a likely reflection of its significant announcements in the world of immunology, the latest price drop is a bit of a mystery. It's possible there could be some profit-selling at play.

The good news today is the Imugene share price is lifting again, up 3.8% trading at 32.5 cents at the time of writing.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Fallers

A bored woman looking at her computer, it's bad news.
Share Fallers

Why Brickworks, Nickel Industries, Polynovo, and Qantas shares are sinking today

These shares are having a difficult time on Tuesday. But why?

Read more »

plummeting gold share price
Gold

This $3 billion ASX 200 gold stock just crashed 15%! Here's why

Investors are punishing the ASX 200 gold stock today. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Capricorn, CBA, Endeavour, and Polynovo shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

Lines of codes and graphs in the background with woman looking at laptop trying to understand the data.
Share Fallers

Why Appen, Mesoblast, Rio Tinto, and Woodside shares are falling today

These shares are falling more than most on Thursday. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Coles, Ioneer, Treasury Wine, and Woolworths shares are falling today

These shares are having a tough time on hump day. But why?

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Healthco, Life360, Mineral Resources, and Origin Energy shares are sinking today

These shares are having a tough time on Tuesday. But why?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Aurizon, Brainchip, Clarity, and Domino's shares tumbling today

These shares are under pressure on Monday. What's going on?

Read more »

A business woman looks unhappy while she flies a red flag at her laptop.
Share Fallers

These were the worst-performing ASX 200 shares in February 2025

These shares were sold off last month. Let's see what happened to them.

Read more »